VitaSpring Biomedical Co. Ltd.
VSBC
$1.00
$0.000.00%
OTC PK
| 10/31/2022 | 07/31/2022 | 04/30/2022 | 01/31/2022 | 10/31/2021 | |
|---|---|---|---|---|---|
| Revenue | 109.87% | 138.40% | 740.08% | 2,161.56% | 59,210.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 109.87% | 138.40% | 740.08% | 2,161.56% | 59,210.00% |
| Cost of Revenue | 77.68% | 111.47% | 871.44% | 2,509.71% | 19,420.00% |
| Gross Profit | 184.77% | 195.87% | 579.60% | 1,739.57% | 15,948.89% |
| SG&A Expenses | 10.63% | 28.66% | 15.33% | -3.50% | 443.59% |
| Depreciation & Amortization | 1,325.00% | 1,325.00% | -- | -- | 700.00% |
| Other Operating Expenses | 33.33% | -63.64% | -12.50% | -12.50% | -62.50% |
| Total Operating Expenses | 56.96% | 86.94% | 360.26% | 463.08% | 1,517.82% |
| Operating Income | 2,399.41% | 2,127.01% | 672.50% | 405.58% | 64.95% |
| Income Before Tax | 2,334.03% | 2,225.57% | 672.67% | 404.88% | 55.66% |
| Income Tax Expenses | 536.94% | 617.94% | 671.76% | -- | -- |
| Earnings from Continuing Operations | 27,429.41% | 758.39% | 672.93% | 365.64% | 102.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 27,429.41% | 758.39% | 672.93% | 365.64% | 102.85% |
| EBIT | 2,399.41% | 2,127.01% | 672.50% | 405.58% | 64.95% |
| EBITDA | 625.15% | 1,093.17% | 454.94% | 370.48% | -55.95% |
| EPS Basic | 2,150.00% | 1,400.00% | 346.15% | 255.00% | 109.09% |
| Normalized Basic EPS | 3,500.00% | 3,700.00% | 383.33% | 280.00% | 105.88% |
| EPS Diluted | 2,150.00% | 1,400.00% | 346.15% | 255.00% | 109.09% |
| Normalized Diluted EPS | 3,500.00% | 3,700.00% | 383.33% | 280.00% | 105.88% |
| Average Basic Shares Outstanding | -5.12% | 14.64% | 45.42% | 97.94% | 303.25% |
| Average Diluted Shares Outstanding | -5.12% | 14.64% | 45.42% | 97.94% | 303.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |